ArticleClinical rheumatology2026
Inflammatory cytokines mediate the common genetic and immunological background between rheumatoid arthritis and osteoporosis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEvidence for the association between rheumatoid arthritis (RA) and osteoporosis (OP) remains inconsistent, and the role of inflammatory cytokines in mediating this association remains unclear.
methodsThis study used linkage disequilibrium score regression (LDSC), Mendelian randomization (MR), and colocalization analyses to assess the association between RA and OP. Mediation MR analysis was conducted to explore the mediating role of inflammatory cytokines. Multitrait analysis of GWAS enhanced statistical power and identified novel genetic associations. Independent risk loci were examined using GCTA-COJO, PLACO, and FUMA analyses. Risk-associated genes were identified by integrated MAGMA, SMR, and TWAS methods, while BLISS analysis revealed relevant proteins. The GEO database was used to validate pleiotropic gene expression.
resultsGenetic correlation (rg = 0.171), causal association (OR = 1.103), and colocalization analysis (PPH4 = 0.99) together confirmed a genetic link between RA and OP. Interleukin (IL)-17 mediated the RA-OP association. The SNPs rs11574914 and rs11889341 are MTAG-RA independent risk loci. Twenty-five RA-related risk genes are specifically expressed in the lymph node and tonsils. FCRL3 regulates the RA immune infiltration microenvironment.
conclusionsIL-17 promotes the progression of RA to OP; FCRL3 regulates the immune infiltration microenvironment of RA and is a potential therapeutic target. Key Points • Genetic correlation, MR, and colocalization analyses confirm a shared genetic basis between RA and OP. • IL-17 is identified as a key inflammatory mediator driving the progression from RA to OP. • Multi-trait GWAS and integrative post-GWAS analyses uncover novel RA-specific loci and 25 immune-related risk genes. • FCRL3 regulates immune cell infiltration in RA and emerges as a potential therapeutic target for inflammation-induced bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.